<DOC>
	<DOCNO>NCT01192035</DOCNO>
	<brief_summary>BACKGROUND : Since 1996 combination three drug mainstay human immunodeficiency virus ( HIV ) treatment . The important type drug call nucleotide reverse transcriptase inhibitor ( NRTIs ) , non-nucleotide reverse transcriptase inhibitor ( NNRTIs ) protease inhibitor ( PIs ) Response treatment measure increase CD4+ cell count decrease HIV viral load . A major problem development resistance . NNRTIs recommend part first-line treatment HIV Africa many Africans slow NNRTI clearance Caucasians make susceptible development resistance case treatment interruption . PIs might therefore good option African setting low adherence . AIM : To evaluate two different treatment regimens HIV-1 infected patient : A ) A NNRTI ( efavirenz/nevirapine ) base regimen B ) A PI ( ritonavir-boosted lopinavir ) base regimen regard treatment outcome . HYPOTHESIS : Treatment PI superior treatment NNRTI due less development resistance . METHODS : Treatment-naïve adult HIV-1 patient enrol exist cohort The West African Retrovirus Acquired Immune Deficiency ( WARAID ) cohort Guinea Bissau CD4+ cell count ≤ 350 cells/µL and/or clinical sign immune suppression ( World Health Organization ( WHO ) clinical stage 3 4 ) randomise 1:1 : Treatment A : 2 NRTIs ( lamivudine either zidovudine stavudine ) 1 NNRTI ( efavirenz nevirapine ) Treatment B : 2 NRTIs ( treatment A ) 1 PI ( ritonavir-boosted lopinavir ) . Primary outcome : Viral load suppression &lt; 400 copies/ml 12 month enrolment . PERSPECTIVES : Guidelines treatment HIV Africa less copy guideline use Europe North America . Genetic difference pharmacokinetics , woman infect Africa difficulty ensure good adherence mean result obtain Caucasian patient directly transferrable African patient . The result study hopefully help guide treatment HIV Africa future . The investigator believe HIV infected people West Africa deserve evidence-based medicine develop country .</brief_summary>
	<brief_title>PI NNRTI First-line Treatment HIV West Africa - PIONA Trial</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Antiretroviral treatment ( ART ) naïve HIV1 infect patient . Women receive ART pregnancy include . Age ≥ 18 year CD4+ cell count ≤ 350 cells/µL and/or Clinical sign immune suppression ( WHO clinical stage 3 4 ) irrespective CD4+ cell count . Tuberculosis ( TB ) treatment rifampicin time enrolment . Coinfection HIV2 . Grade 3 4 alanine transaminase ( ALAT ) elevation ( &gt; 5 time upper normal limit ) . Patients cerebral disturbance complicate ability give inform consent follow treatment regime .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Africa , Western</keyword>
	<keyword>Antiretroviral Therapy , Highly Active</keyword>
</DOC>